Integration of Chemoinformatics and Multi-Omics Analysis Defines ECT2 as a Potential Target for Cancer Drug Therapy

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Epithelial cell transforming 2 (ECT2) is implicated as an oncogene in various human cancers.
• Previous studies suggest a correlation between ECT2 and cancer progression, but a comprehensive analysis is lacking.

Purpose of the Study:

• To investigate the expression, oncogenic behavior, and clinical significance of ECT2 across multiple human cancers.
• To explore ECT2's role in the tumor microenvironment and its impact on patient prognosis.
• To identify potential ECT2-targeting antitumor agents.

Main Methods:

• Differential gene and protein expression analysis of ECT2 in tumor versus normal tissues.
• Correlation analysis of ECT2 expression with tumor stage, grade, metastasis, and patient survival.
• Assessment of ECT2 methylation and phosphorylation status.
• Investigation of ECT2's impact on immune cell infiltration (MDSC, NKT cells).
• Screening for ECT2 inhibitors as potential anticancer drugs.

Main Results:

• ECT2 is significantly upregulated in various human tumors at both mRNA and protein levels.
• ECT2 upregulation correlates with increased myeloid-derived suppressor cell (MDSC) infiltration and decreased natural killer T (NKT) cell levels.
• Elevated ECT2 expression is associated with poor patient survival.
• Identified potential ECT2 inhibitors with antitumor properties.

Conclusions:

• ECT2 serves as a prognostic and immunological biomarker in human cancers.
• ECT2 influences the tumor immune microenvironment, contributing to adverse outcomes.
• Targeting ECT2 with identified inhibitors presents a promising therapeutic strategy for cancer treatment.